Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q2 2015 · 10-Q
Revenue$8.91M$8.91M−8.6% vs Q2 2014 Net Income$407.40K$407.40K−43.6% vs Q2 2014 EPS Diluted$0.02$0.02−50.0% vs Q2 2014 Operating Income$673,931−44.6% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$2,080,414+154.5% Margins · derivedOperating margin7.6%−4.9 pt vs Q2 2014
Net margin4.6%−2.8 pt vs Q2 2014
ended Jun 30, 2015 · filed Aug 7, 2015 · 38 d after period end